Making the Best Use of Available Weapons for the Inevitable Rivalry-Resistance to EGFR-TKIs

The emergence of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) revolutionized the treatment of advanced-stage non-small cell lung cancer (NSCLC). Detected in more than 50% of late-stage lung adenocarcinoma in Asian patients, the EGFR mutation was regarded as a golden mutati...

Full description

Bibliographic Details

Published in:	Biomedicines
Main Authors:	Dongyu Li, Jingnan Wang, Chengming Liu, Yuejun Luo, Haiyan Xu, Yan Wang, Nan Sun, Jie He
Format:	Article
Language:	English
Published:	MDPI AG 2023-04-01
Subjects:	EGFR-TKIs NSCLC lung cancer sequential therapy resistant mechanisms
Online Access:	https://www.mdpi.com/2227-9059/11/4/1141